AKBA Akebia Therapeutics, Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001517022
AI RATING
SELL
65% Confidence

Investment Thesis

Akebia demonstrates strong revenue growth of 47.5% YoY, but fundamental financial health is deteriorating with negative operating cash flow of -$21.2M, unprofitable operations, and dangerously low stockholders' equity of only $27.4M against $335.1M in liabilities. The 1.79x debt-to-equity ratio combined with ongoing cash burn creates material financial distress risk despite the substantial $162.6M cash position.

Strengths

  • + Strong revenue growth of 47.5% YoY demonstrates market traction and product demand
  • + Substantial absolute cash balance of $162.6M provides approximately 8 quarters of runway at current burn rates
  • + Improving diluted EPS trend with 93.9% YoY improvement, showing progress toward profitability

Risks

  • ! Negative operating cash flow of -$21.2M and free cash flow of -$21.3M indicate the company is burning cash despite revenue growth
  • ! Critically low stockholders' equity of $27.4M represents only 7.5% of total assets, creating severe financial stress risk and high likelihood of dilutive capital raises
  • ! High leverage with debt-to-equity ratio of 1.79x combined with negative profitability increases default risk and limits financial flexibility

Key Metrics to Watch

Financial Metrics

Revenue
53.5M
Net Income
-9.1M
EPS (Diluted)
$-0.03
Free Cash Flow
-21.3M
Total Assets
362.5M
Cash
162.6M

Profitability Ratios

Gross Margin N/A
Operating Margin -8.8%
Net Margin -16.9%
ROE -33.1%
ROA -2.5%
FCF Margin -39.7%

Balance Sheet & Liquidity

Current Ratio
1.40x
Quick Ratio
1.33x
Debt/Equity
1.79x
Debt/Assets
92.4%
Interest Coverage
N/A
Long-term Debt
48.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-16T08:31:11.833192 | Data as of: 2026-03-31 | Powered by Claude AI